Business
Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting
Company to Host Analyst and Investor Conference Call on November 12 at 4:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Alector,
About this update from Alector, Inc.
[{"type":"text","content":"Company to Host Analyst and Investor Conference Call on November 12 at 4:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference being held November 9-12, 2021 virtually and in Boston, and the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting held November 12-14, 2021 virtually and in Washington, D.C. Among the data being presented at CTAD are twelve-month biomarker and clinical data from the open-label Phase 2 INFRONT-2 study evaluating AL001 in individuals with frontotemporal dementia due to progranulin gene mutation (FTD-GRN). Alector will also present data from its Phase 1 study of AL003 in healthy volunteers and participants with Alzheimer’s disease. AL003 is being developed in collaboration with its partner, AbbVie. At SITC, Alector will provide an update on AL009, a first-in-class multi-Siglec inhibitor that enhances innate and adaptive immunity to cancer by blocking a critical glycan checkpoint pathway. Alector plans to host a conference call to review these data and the progress across its pipeline on November 12, 2021, at 4:00 p.m. ET. Presentations at CTAD Oral Presentation: Presentation Title: Update on the Phase 2 Study of AL001 in Frontotemporal Dementia Patients Carrying a Granulin Mutation (OC32)Presenter: Sam Jackson, M.D., MBA, Alector’s interim Chief Medical OfficerSession Date and Time: November 12, 2021 at 1:50 p.m. ET Poster Presentations:Poster presentations will be available for on-demand viewing starting November 9, 2021. Poster Title: A Phase 1 Study of AL003 in Healthy Volunteers and Participants with Alzheimer’s Disease (P45)Theme: Clinical trials: resultsPresenting Author: Michael Ward, Ph.D., Senior Director, Clinical Science, Alector Poster Title: A First-in-human Study of the Anti-Sortilin Antibody AL101 (P46)Theme: Clinical trials: resultsPresenting Author: Michael Ward, Ph.D., Senior Director, Clinical Science, Alector Poster Title: Design of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 IN FTD-GRN (P71)Theme: New therapies and clinical trialsPresenting Author: Sam Jackson, M.D., MBA, interim Chief M...